Summary
Previous work in this laboratory, as well as observations reported in the literature, indicate that the adrenal medulla contains dopamine (DA) receptors of the D-2 subtype, which among other things are capable of controlling the DA level in rat adrenal glands. To further characterize the DA receptors involved in the control of the adrenal DA level, the effects of 9 DA receptor agonists with various intrinsic activities were compared. After various periods of drug administration the rats were killed by decapitation and the DA content of the adrenal glands and the DOPAC content of the forebrain were measured by high-performance liquid chromatography with electrochemical detection. All the investigated DA receptors agonists caused an increase in adrenal DA level, although statistical significance was not reached in one case /(−)-HW165/. Domperidone, a DA D-2 receptor antagonist which does not readily cross the blood brain barrier, blocked the DA-elevating effects of apomorphine, quinpirole, B-HT 920 and both enantiomers of 3-PPP. For the two ergolines terguride and SDZ 208-920 the blockade by domperidone was not complete, suggesting that their effects are mediated not only through DA, but also through other receptor systems. The dose of domperidone used (3 mg/kg) had but a marginal influence on brain DOPAC levels, supporting the almost exclusively peripheral effect of this agent. Our data indicate that the DA D-2 receptors which control the DA level in the adrenal medulla in rats, have characteristics similar to, though not identical with the autoreceptors in the forebrain.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andén N-E, Nilsson H, Ros E, Thornström U (1983) Effects of B-HT 920 and B-HT 933 on dopamine and noradrenaline autoreceptors in the rat brain. Acta Pharmacol Toxicol 52: 51–56
Andén N-E, Grabowska-Andén M (1987) Increased motor activity following combined stimulation of B-HT 920-sensitive and D-1 dopamine receptors. Acta Physiol Scand 131: 157–158
Andén N-E, Grabowska-Andén M (1990) B-HT 920 is a full agonist at both pre- and postsynaptic D-2 dopamine receptors. J Neural Transm 79: 209–214
Carlsson A (1987) Pharmacology of selective dopamine receptor agonists. In: Mutscheler E, Winterfeldt E (eds) Trends in medical chemistry. VCH Verlagsgesellschaft mbH, Weinheim, pp 313–321
Clark D, Hjorth S, Carlsson A (1985 a) Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 62: 1–52
Clark D, Hjorth S, Carlsson A (1985 b) Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm 62: 171–207
Coward DM, Dixon AK, Urwyler S, Vigouret J-M (1988) Pharmacological properties of SDZ 208-912: a potential high potency, non-classical neuroleptic. Pharmacopsychiatry 21: 312–313
Freed WJ, Wyatt RJ (1987) Brain tissue transplantation in animal models of extrapyramidal motor dysfunction. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 471–479
Hjorth S, Clark D, Carlsson A (1985) Lack of functional evidence for the involvement of sigma opiate receptors in the action of the 3-PPP enantiomers on central dopaminergic systems: discrepancies between in vitro and in vivo observations. Life Sci 37: 673–684
Hjort S, Svensson K, Carlsson A, Wikström H, Andersson B (1986) Central dopaminergic properties of HW-165 and its enantiomers; Transoctahydrobenzo(f)quinoline congeners of 3-PPP. Naunyn-Schmiedebergs Arch Pharmacol 333: 205–218
Hjorth S, Carlsson A (1987) Postsynaptic dopamine (DA) receptor stimulator properties of the putative DA autoreceptor-selective agonist B-HT 920 uncovered by co-treatment with the D-1 agonist SK & F38393. Psychopharmacology 93: 534–537
Karobath M, Coward D, Enz A, Haefliger W, Jaton A, Markstein R, Palacios JM, Shearman G, Supavilai P, Wiederhold KH, Vigouret JM (1988) Functional effects of partial D2 dopamine receptor agonists. In: Progress in catecholamine research, part B. Central aspects. Alan R Liss, pp 19–26
Kehr W (1984) Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism. Eur J Pharmacol 97: 111–119
Kujacic M, Svensson K, Löfberg L, Carlsson A (1990) Acute changes in dopamine levels in rat adrenal glands after administration of dopamine receptor agonists and antagonists. Eur J Pharmacol 177: 163–170
Laduron MP, Leysen EJ (1979) Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol 28: 2161–2165
Liljefors T, Wikström H (1986) A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series. J Med Chem 29: 1896–1904
Lyon RA, Titeler M, Bigornia L, Schneider AS (1987) D2 dopamine receptors on bovine chromaffin cell membranes: identification and characterization by (3 H)N-methylspi-perone binding. J Neurochem 48: 631–635
Quik M, Bergeron L, Mount H, Philie J (1987) Dopamine D2 receptor binding in adrenal medulla: characterization using (3 H)spiperone. Biochem Pharmacol 36: 3707–3713
Schalling M, Dagerlind Å, Goldstein M, Ehrlich M, Greengard P, Hökfelt T (1990) Comparison of gene expression of the dopamine D2 receptor and DARPP-32 in rat brain, pituitary and adrenal gland. Eur J Pharmacol Mol Pharmacol Sect 188: 277–281
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kujacic, M., Svensson, K., Löfberg, L. et al. Dopamine receptors, controlling dopamine levels in rat adrenal glands — comparison with central dopaminergic autoreceptors. J. Neural Transmission 84, 195–209 (1991). https://doi.org/10.1007/BF01244970
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01244970